老年性哮喘诊治进展  

New Progress in Diagnosis and Treatment of Senile Asthma

作　　者：张泉三[1] 徐晓虹[1] 孙兆家[1] 战炳炎 

机构地区：[1]青岛市市立医院急诊科,山东青岛266011 [2]青岛市第九人民医院呼吸内科,山东青岛266001

出　　处：《医学综述》2017年第13期2601-2605,2610,共6页Medical Recapitulate

摘　　要：随着中国进入老龄化社会,老年性哮喘的发病率也呈现逐年升高的趋势。老年性哮喘是支气管哮喘的重要组成部分,近年来国内外学者已给予了重视,肺功能和痰液中特异性蛋白在老年性哮喘的诊断中有重要作用。支气管哮喘的常规治疗药物,如茶碱、吸入性糖皮质激素等在老年性哮喘患者中的合理应用及测定呼出气一氧化氮观察老年性哮喘的治疗效果是目前的研究热点;特异性免疫治疗及靶向治疗的新进展对于老年性哮喘的治疗有重要意义。As China is entering the aging society, the elderly asthma incidence is increasing year by year. Senile asthma is a kind of important clinical phenotype of asthma, to which the domestic and foreign scholars have given considerable attention in recent years, and the reasonable application of pulmonary function and specific protein in sputum play an impor- tant role in the diagnosis of senile asthma. Rational use of conventional therapy of bronchial asthma such as theophylline and inhaled corticosteroids in the patients and determination of fractional exhaled nitric oxide to observe the therapeutic effect of senile asthma is the hotspot of the research in this area. The progress in specific immunotherapy and targeted therapy for senile asthma has great significance for the clinical treatment.

关 键 词：老年性哮喘 肺功能 炎性标志物 支气管扩张剂 糖皮质激素 

分 类 号：R562.25[医药卫生—呼吸系统]